Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IcoSema versus semaglutide once weekly in adults with inadequately controlled type 2 diabetes mellitus previously treated with a GLP-1 receptor agonist
MOH_2021-12-23_010239Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing IcoSema once weekly with Semaglutide once weekly (2 arms). Started Dec 2021; status: completed.
02
Drugs
icosemasemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2021-12-23_010239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-23_010239.